13F Holdings
中文EN

BMRN BIOMARIN PHARMACEUTICAL INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1048477 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY-103.7%
TTM EPS YoY-103.7%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—

Margins

Gross margin76.0%
Operating margin3.1%
Net margin-0.5%
FCF margin15.3%
EBITDA margin4.7%

Returns

ROE-0.3%
ROA-0.2%
ROIC (approx.)0.8%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets45.9%
Debt / equity0.67x
Current ratio2.44x
Interest coverage0.89x

Cash quality & payout

Operating cash flow / net income-35.40x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.22B$2.85B$2.42B$2.10B$1.85B
Cost of revenue$717.44M$580.24M$532.06M$503.02M$470.51M
Gross profit$2.50B$2.27B$1.89B$1.59B$1.38B
R&D expense$921.93M$747.18M$746.77M$649.61M$628.79M
SG&A expense$1.15B$1.01B$892.41M$823.24M$759.38M
Operating income$409.48M$484.21M$185.77M$160.97M-$82.34M
Interest expense$10.90M$12.67M$17.34M$15.97M$15.34M
Pretax income$482.48M$541.76M$188.56M$149.58M-$75.35M
Income tax$133.58M$114.90M$20.92M$8.02M-$11.27M
Net income$348.90M$426.86M$167.65M$141.56M-$64.08M
EBITDA$489.04M$580.64M$290.16M$262.94M$25.70M
EPS (basic)1.822.250.890.76-0.35
EPS (diluted)1.802.210.870.75-0.35
Weighted avg. shares (diluted)197.39M196.71M191.59M188.96M182.85M
Balance sheet
Cash & equivalents$1.31B$942.84M$755.13M$724.53M$587.28M
Short-term investments$248.93M$194.86M$318.68M$567.01M$426.60M
Receivables$908.21M$660.53M$633.70M$461.32M$373.40M
Inventory$1.30B$1.23B$1.11B$894.08M$776.67M
Current assets$3.95B$3.23B$2.96B$2.75B$2.27B
PP&E, net$952.51M$1.04B$1.07B$1.07B$1.04B
Goodwill$196.20M$196.20M$196.20M$196.20M$196.20M
Intangibles$213.84M$255.28M$294.70M$338.57M$388.65M
Total assets$7.59B$6.99B$6.84B$6.38B$6.00B
Current liabilities$759.03M$606.99M$1.18B$588.88M$546.50M
Short-term debt$0————
Long-term debt$597.18M————
Total debt$597.18M————
Total liabilities$1.51B$1.33B$1.89B$1.77B$1.74B
Shareholders' equity$6.09B$5.66B$4.95B$4.60B$4.27B
Net debt-$714.50M————
Shares outstanding192.30M190.76M188.60M186.25M183.91M
Cash flow statement
Operating cash flow$827.99M$572.84M$159.26M$175.90M$304.54M
Capital expenditure$103.04M$85.42M$96.69M$120.96M$95.58M
Free cash flow$724.96M$487.42M$62.57M$54.94M$208.96M
Investing cash flow-$414.24M$136.49M-$111.24M-$20.03M-$366.31M
Financing cash flow-$42.39M-$526.45M-$18.73M-$18.65M-$48,000
Depreciation & amortization$79.56M$96.43M$104.39M$101.97M$108.04M
Stock-based compensation$181.41M$201.57M$207.10M$196.31M$197.26M
Share buybacks———$0$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.